appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Bafna Pharmaceuticals Ltd
BAFNAPH
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Price
Price Upside
—
Earnings
Earnings Growth
—
Revenue
Rev. Growth
—
Company Profile
Bafna Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the manufacture of drugs and medicines.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Copy of Newspaper Publication
Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication in connection with Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2024 | Download
Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication in connection with Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2024 | Download
Cash Dividend
Final • Div/Share: ₹ 0.6
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant